Fernando Martins Braga

Dr. Fernando Martins Braga

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AMAntonio Montoto-Marqués
Antonio Montoto-Marqués
JPJesús Benito Penalva
Jesús Benito Penalva
MFMaría Elena Ferreiro-Velasco
María Elena Ferreiro-Velasco
MWMark Wright
Mark Wright
SBSebastián Salvador-De la Barrera
Sebastián Salvador-De la Barrera
JVJoan Vidal
Joan Vidal
Recovery from traumatic spinal cord injury (tSCI) is challenging due to the limited regenerative capacity of the central nervous system to restore cells, myelin, and neural connections. At the clinical level, the fundamental pillars of treatment are the reduction in secondary damage (neuroprotection) and rehabilitation; these are the tools we have to mitigate the disability caused by spinal cord injury (SCI). To date, the treatments on which neuroprotection has been based are the prevention of acute respiratory failure to avoid hypoxia, early hemodynamic control, neuroprotective drugs and surgical management. Optimizing early hemodynamic control to ensure adequate spinal cord perfusion may be key to the management of SCI. While neuroprotective agents like methylprednisolone have fallen into disuse, several promising therapies are currently being tested in clinical trials. In terms of surgical treatment, although their impact on neurological recovery remains debated, appropriate early bone decompression followed by duroplasty in selected cases is increasingly recommended. Advances in cell therapies hold significant potential for enhancing both clinical and functional outcomes in SCI patients. Moreover, emerging neuromodulation techniques, such as transcutaneous and epidural stimulation, along with innovations in rehabilitation technologies—such as robotic systems and exoskeletons—are becoming indispensable tools for improving locomotion and overall mobility in individuals with SCI. This article provides an update on the advances in neuroprotection against secondary damage caused by tSCI, in cellular therapies, and in new rehabilitation therapies.

1 March 2003 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
PMPaulo M. Porto de Melo
Paulo M. Porto de Melo
PKPaulo Abdo Do Seixo Kadri
Paulo Abdo Do Seixo Kadri
Jean G. de OliveiraJean G. de Oliveira
Jean G. de Oliveira
FBFernando Martins Braga
Fernando Martins Braga
A incidência de clipagem de aneurismas em que permanecem restos da dilatação varia, nas séries estudadas, de 1-10%. Deste percentual, 21,8% é devido à migração do clipe.D´Angelo e seus colaboradores (1998), encontraram 1 a 10% de aneurismas residuais. Sugerem que quando o resíduo for menor que 2 mm seja realizado estudo angiográfico entre 3-5 anos após o procedimento cirúrgico; se entre 2 e 4 mm, este estudo deve ser mais precoce, dentro dos primeiros 6 meses e depois anualmente; e, quando maior que 4 mm, a reabordagem. Apresentamos os casos de duas pacientes submetidas a tratamento cirúrgico de aneurismas intracranianos, com intra-operatório sem intercorrências e que, em exames ulteriores, evidenciaram migração do clipe de sua posição original. É apresentada, ainda, revisão da literatura.

17 July 2025 in Spinal Cord Series and Cases
Verified
Journal Article
Closed access
FBFernando Martins Braga
Fernando Martins Braga
SASergiu Albu
Sergiu Albu
CFCecilia Mariño Fernández
Cecilia Mariño Fernández
VSVirginia Martínez Santana
Virginia Martínez Santana
JPJesús Benito Penalva
Jesús Benito Penalva
JSJoan Vidal Samsó
Joan Vidal Samsó

4 November 2024 in The Journal of Spinal Cord Medicine
Verified
Journal Article
Closed access
FBFernando Martins Braga
Fernando Martins Braga
MVMargarita Vallès
Margarita Vallès
HKHatice Kumru
Hatice Kumru
A previously healthy 40-year-old woman experienced a sudden complete tetraplegia (C8, AIS-A). MRI revealed a C6/C7 disc herniation surrounded by an epidural haematoma. Physicians must recognize acute, non-traumatic disc herniation as a potential cause of spinal cord injury, urging prompt diagnosis and intervention.

26 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
FBFernando Martins Braga
Fernando Martins Braga
HKHatice Kumru
Hatice Kumru
JPJesús Benito Penalva
Jesús Benito Penalva
JVJoaquim Vives
Joaquim Vives
RBRuth Coll Bonet
Ruth Coll Bonet
JVJoan Vidal
Joan Vidal
Background/Objectives: Chronic traumatic spinal cord injury (SCI) causes persistent neurological deficits for which no clinically effective regenerative therapy is currently available. Mesenchymal stromal/stem cells (MSCs), particularly Wharton’s jelly-derived MSCs (WJ-MSCs), demonstrate immunomodulatory and neurotrophic potential. This phase I/II study evaluated the safety and efficacy of intrathecal allogeneic WJ-MSC administration in individuals with chronic incomplete cervical SCI. Methods: In this multicentre, randomised, double-blind, placebo-controlled trial (NCT05054803, EudraCT 2021-000346-18), 18 participants with chronic (1–5 years post-injury) incomplete cervical SCI (AIS B–D) received two intrathecal injections of WJ-MSCs (0.7–1.3 × 106 viable cells/kg) or a placebo at baseline and 3 months. Seventeen participants completed the 12-month follow-up. Primary outcomes assessed safety, and secondary endpoints included International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor and sensory scores, spasticity, neuropathic pain, functional independence, neurophysiological measures, and quality of life. Results: Intrathecal WJ-MSC administration was safe and well tolerated. Eighty adverse events occurred (placebo: 26; WJ-MSC: 54), predominantly mild or moderate; four severe events were unrelated to treatment. Both groups demonstrated significant within-group improvements in total motor scores at 12 months, with no between-group difference. No treatment effects were observed for sensory scores, electrophysiological measures, functional independence, spasticity, pain, or patient-reported outcomes. Conclusions: In this first randomised, placebo-controlled trial evaluating intrathecal WJ-MSCs in chronic incomplete cervical SCI, WJ-MSC administration demonstrated a favourable safety profile; however, no significant between-group differences were detected relative to the placebo. Given the limited sample size and early-phase design, the efficacy findings should be interpreted cautiously. Future research should explore enhanced cell products, intensified dosing schedules, optimised delivery strategies, early intervention, and multimodal therapeutic combinations.

28 September 2026 in Reports
Verified
Journal Article
Open access
PDF file
FBFernando Martins Braga
Fernando Martins Braga
ESElena Tello Santamaria
Elena Tello Santamaria
MVMargarita Vallès
Margarita Vallès
HKHatice Kumru
Hatice Kumru
Background and Clinical Significance: Non-contiguous traumatic spinal cord injury (SCI) can be difficult to recognise and classify in severe polytrauma, especially when traumatic brain injury (TBI) and limb injuries limit neurological examination. Case Presentation: A 17-year-old male was involved in a motorcycle accident resulting in severe polytrauma with TBI. Brain magnetic resonance imaging (MRI) showed a grade III diffuse axonal injury. Trauma computed tomography (CT) identified C2 and T3–T5 vertebral fractures. Spinal MRI revealed a non-haemorrhagic C3–C6 contusive myelopathy, a T4 spinal cord contusion, and a thoracic posterior epidural haematoma. He underwent posterior T2–T7 fixation. Acute neurological examination was limited by impaired consciousness and associated injuries. At four months, the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessment showed a neurological level of C2, and a total motor score of 55. Electrodiagnostic testing showed active bilateral C5–T1 denervation. At seven months and one year, the total motor score increased to 63 and 82, respectively, accompanied by substantial functional improvement. Conclusions: In severe polytrauma with TBI, non-contiguous SCI should be considered when neurological examination is unreliable. In non-contiguous SCI, clinical assessment should integrate neurological examination, including quantitative motor and sensory scores, with imaging and neurophysiological studies, cognitive status, associated injuries, and functional outcomes.